Briacell Therapeutics Corp BCTX

$3.47 -0.12 (-3.20%)

Valuation

Market cap
32,223,000
Revenue TTM
$0
Net income TTM
$-34,900,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
41,304
Avg volume
99,372
Day's range
$3.44 – $3.60
Shares out
8,732,000
Stochastic %K
57%
Beta
1.26
Analysts
—
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604-921-1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

letsdodiz Nov 12, 6:22 PM
$BCTX their impulse reaction to where do you see bctx in 5 years is we maybe won’t be a company anymore just screams they maybe have something lined up pending results. They also seem very relaxed about additional funding/ future capital raise questions. The non answer on whether OS is the main driver in pushing the date from 1H 26 to Q1 27 is confirmation that the OS is good. Enrollment has not been a problem.
4 replies
AliceFireSteam Nov 12, 6:12 PM
$BCTX "I really want to answer that question, but I don't think I really can" "I really am fond of not being in jail. So it's definitely coming out very rapidly"
1 replies
Biotechlineup Nov 12, 6:09 PM
$BCTX my quick take on the last road show presentation . Still shooting for end of year read out, they pushed it to maybe 1st qtr. The question was asked multiple times and when pushed they changed it to “early” next year. So on track for that .6 HR. They reiterated that they have enough cash to get through the read out. Dilution was asked multiple times and possible partnerships. I guess the continued questions pushed them because the last time they answered it as “ possible and probable “ probably is an important statement, means they are “ probably “ in active discussions. They wouldn’t answer this time on total recruitment, however on a previous conference call they had already mentioned in the present tense 177 each arm with recruitment going hockey stick. So reason they didn’t answer? Don’t know , maybe they were told not to. My guess they are already fully recruited and it’s just playing out .
0 replies
AliceFireSteam Nov 12, 6:05 PM
$BCTX transcription added
1 replies
PensiveInvestor Nov 12, 5:59 PM
$BCTX Why did they even need this presentation? there was nothing new compared to the last presentation?
0 replies
BCTX20bMC Nov 12, 5:53 PM
$BCTX they couldn't be anymore loud & clear...they have enough cash to get them to P3 readout. 🌋
0 replies
Manwiththeplan Nov 12, 5:49 PM
$BCTX phase 3 update could be next year
0 replies
smallpower17 Nov 12, 5:26 PM
$BCTX Jamieson is wearing a much more fancy shirt and tie combo - very bullish signal. Bill's shirt and tie combo can only be described as bizarre.
0 replies